Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...

The other, the Federal Trade Commission, is already conducting a major investigation of pharmacy benefit managers and is suing over their pricing practices regarding insulin ... three PBMs are the ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

The other, the Federal Trade Commission, is already conducting a major investigation of pharmacy benefit managers and is suing over their pricing practices regarding insulin. She was speaking just ...

Drugmakers blame middlemen known as pharmacy benefit managers for high drug prices. PBMs negotiate drug prices and rebates ...

The price of insulin has been a major flashpoint ... Drugmakers blame middlemen known as pharmacy benefit managers for high drug prices. PBMs negotiate drug prices and rebates with manufacturers ...

In recent years, many patients like Mitchell have faced soaring insulin costs. These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and ...

By taking steps to hold middlemen ... Affordable Insulin Now Act moves towards the US Senate. Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi ...

Kamala Harris and Donald Trump are both pledging to make health care more affordable in the U.S., but have largely different ...

INSULIN LITIGATION DEEP-DIVE — As Congress ... in a New Jersey district court against the three major pharmacy middlemen — CVS Caremark, Express Scripts and OptumRx — and three insulin ...